These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 29858219)

  • 1. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
    Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
    Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarker Assessment of HR Deficiency, Tumor
    Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
    Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
    BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
    Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
    Zhao EY; Shen Y; Pleasance E; Kasaian K; Leelakumari S; Jones M; Bose P; Ch'ng C; Reisle C; Eirew P; Corbett R; Mungall KL; Thiessen N; Ma Y; Schein JE; Mungall AJ; Zhao Y; Moore RA; Den Brok W; Wilson S; Villa D; Shenkier T; Lohrisch C; Chia S; Yip S; Gelmon K; Lim H; Renouf D; Sun S; Schrader KA; Young S; Bosdet I; Karsan A; Laskin J; Marra MA; Jones SJM
    Clin Cancer Res; 2017 Dec; 23(24):7521-7530. PubMed ID: 29246904
    [No Abstract]   [Full Text] [Related]  

  • 8. Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.
    Pikkusaari S; Tumiati M; Virtanen A; Oikkonen J; Li Y; Perez-Villatoro F; Muranen T; Salko M; Huhtinen K; Kanerva A; Koskela H; Tapper J; Koivisto-Korander R; Joutsiniemi T; Haltia UM; Lassus H; Hautaniemi S; Färkkilä A; Hynninen J; Hietanen S; Carpén O; Kauppi L
    Clin Cancer Res; 2023 Aug; 29(16):3110-3123. PubMed ID: 36805632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
    Mukhopadhyay A; Plummer ER; Elattar A; Soohoo S; Uzir B; Quinn JE; McCluggage WG; Maxwell P; Aneke H; Curtin NJ; Edmondson RJ
    Cancer Res; 2012 Nov; 72(22):5675-82. PubMed ID: 23066035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
    Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
    Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
    Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
    BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.
    von Wahlde MK; Timms KM; Chagpar A; Wali VB; Jiang T; Bossuyt V; Saglam O; Reid J; Gutin A; Neff C; Lanchbury JS; Hatzis C; Hofstatter E; Pusztai L
    Clin Cancer Res; 2017 Mar; 23(5):1193-1199. PubMed ID: 27601588
    [No Abstract]   [Full Text] [Related]  

  • 19. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
    Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.